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Background: Survival in follicular lymphoma (FL) is highly variable, even within prognostic groups defined by
tumor grade and the Follicular Lymphoma International Prognostic Index. Studies suggest that germline single
nucleotide polymorphisms (SNPs) may hold prognostic information but further investigation is needed.
Methods: We explored the association between SNPs and FL outcome using two approaches: 1) Two independent
genome-wide association studies (GWAS) of ~300.000 SNPs followed by a meta-analysis encompassing 586 FL patients
diagnosed in Denmark/Sweden 1999–2002 and in the United States 2001–2006; and 2) Investigation of 22
candidate-gene variants previously associated with FL outcome in the Danish/Swedish cohort (N = 373). We
estimated time to lymphoma-specific death (approach 1 and 2) and lymphoma progression (approach 2) with
hazard ratios (HR) and 95% confidence intervals (CI) in a multivariable Cox regression model.
Results: In the GWAS meta-analysis, using a random effects model, no variants were associated with lymphoma-specific
death at a genome-wide significant level (p < 5.0 ×10−8). The strongest association was observed for tightly linked SNPs
on 17q24 near the ABCA10 and ABCA6 genes (rs10491178 HRrandom = 3.17, 95% CI 2.09-4.79, prandom = 5.24 ×10
−8). The
ABCA10 and ABCA6 genes belong to a family of genes encoding for ABC transporter proteins, implicated in multidrug
resistance. In line with a previous study, rs2466571 in CD46 (HR = 0.73, 95% CI 0.58-0.91, p = 0.006) showed nominal
association with lymphoma progression, as did two highly linked SNPs in IL8 (rs4073 HR = 0.78, 95% CI 0.62-0.97,
p = 0.02; rs2227307 HR = 0.75, 95% CI 0.60-0.94, p = 0.01) previously associated with overall survival.
Conclusions: The results suggest a possible role for multidrug resistance in FL survival and add to the evidence
that genetic variation in CD46 and IL8 may have prognostic implications in FL. Our findings need further
confirmation in other independent populations or in a larger multicenter GWAS.
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Candidate gene studyBackground
For most patients with follicular lymphoma (FL) the dis-
ease is incurable and treatment aims to relieve symptoms
and prolong survival [1]. In the clinical setting, established
prognostic markers include tumor grade and the Follicular
Lymphoma International Prognostic Index (FLIPI) [2].
However, marked variation in outcome remains within* Correspondence: fredrik.baecklund@ki.se
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article, unless otherwise stated.each risk group [2], and new prognostic markers are there-
fore desirable for more accurate prognostication and
personalized treatment. In the search for such markers,
several studies have assessed the impact of inherited gen-
etic variation in FL survival [3-18].
There is growing evidence that the tumor microenvir-
onment and the host immune response, partly deter-
mined by host genetics, are important for the clinical
course of FL [19]. Germline genetic variation may fur-
ther affect the metabolism [20] or receptor affinity of
anti-cancer drugs [21] with possible implications for
prognosis. To date, at least 30 specific germline singletral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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kine and immune function genes (e.g., C9, CD46, CD55,
CFH, IL2, IL4R, IL8 and FCGR2A), have been associated
with FL outcome in previous studies [3,4,6-9,11-18]. How-
ever, most studies were small in size (<150 FL cases
[3,4,6,8,11-18]), and the majority of the reported findings
are unconfirmed. In recent genome-wide association stud-
ies (GWAS), an important role for variation in the human
leukocyte antigen (HLA) region has been revealed for risk
of FL, and one variant in the HLA class I region has been
associated both with FL risk and survival [22-26].
To gain additional knowledge of the role of genetic
variation in FL outcome, we explored the association
of ~300.000 SNPs with lymphoma-specific death in two
independent GWAS in Sweden/Denmark [25] and the
USA [22], followed by a full meta-analysis encompassing
a total of 586 FL cases. We also investigated genetic
variants previously reported to be associated with FL
survival as well as recently established FL risk-associated
SNPs for the association with lymphoma-specific death
and progression in the Swedish/Danish (N = 373) and
Swedish datasets (N = 231), respectively.
Methods
This study was approved by the Ethical Review Board in
each country (Sweden: The Regional Ethical Review
Board in Stockholm; Denmark: Scientific Ethics Committee
for the Capital Region of Copenhagen; California, USA:
UCSF Human Research Protection Program, Committee
on Human Subjects Research) and all study participants
gave informed consent.
SCALE study participants
We included cases with FL in the Scandinavian Lymphoma
Etiology (SCALE) study, described in detail elsewhere [27].
Briefly, SCALE is a population-based case–control study of
the etiology of malignant lymphomas conducted in Sweden
and Denmark 1999 to 2002. Overall, 3,740 incident malig-
nant lymphoma patients 18–74 years of age were included.
Through a rapid case ascertainment network, the patients
were identified shortly after diagnosis. Lymphoma subtypes
were reviewed and reclassified according to the WHO clas-
sification [28]. Study participants were restricted to individ-
uals with sufficient knowledge of the Danish or Swedish
language to answer questions in a telephone interview and
without a history of organ transplantation, HIV infection,
or other hematopoietic malignancy. In the study overall,
85% of eligible NHL patients were included. In Sweden, a
detailed registration of subtypes of all eligible patients per-
mitted evaluation of participation rates by NHL subtype,
which was 94% for FL. Early death was an uncommon
reason for non-participation among the FL patients (1%).
Four-hundred ninety-nine (85%) of all interviewed FL pa-
tients also gave blood. The median time from diagnosis tovenipuncture was three months (interquartile range: one to
five months). In SCALE overall, patients who gave blood
were similar to all participating patients with regard to age,
sex and educational level.
Clinical data and follow-up
In Sweden, information about established prognostic fac-
tors (Ann Arbor stage, performance status, number of
involved nodal areas, hemoglobin and lactate dehydro-
genase levels), treatments and signs of progression, was
collected from medical records. Lymphoma progression
was defined as the time to progression, date of start of
second-line treatment or lymphoma-specific death, if no
second-line treatment was given (data only available in
Sweden). Dates and causes of death were obtained
through the Cause of Death registry [29], with complete
follow-up through February 2, 2012. In Denmark, clin-
ical parameters (Ann Arbor stage, performance status,
treatment) and complete follow-up of survival through
December 17, 2009, were obtained from the Danish na-
tional lymphoma database (LYFO) [30]. Lymphoma-
specific death was defined as having lymphoma as the
main underlying cause of death. Based on the number of
FLIPI risk factors, the Swedish cases were classified as
having low, intermediate or high risk of death (0–1, 2
or ≥3 risk factors, respectively). The Danish patients
were classified according to a modified FLIPI based on
age (≥60) and stage (I-II vs. III-IV) only, as low risk if
they had none of these factors, intermediate if they had
one, and high risk if they had two risk factors.
Genotyping
In 400 FL cases for whom a sufficient amount of DNA
was available, genotyping of 317,503 SNPs was con-
ducted at the Genome Institute of Singapore within a
GWAS using the Illumina HumanHap 300 (version 1.0)
array [25]. The resulting dataset was filtered on the basis
of genotyping call rates (≥95%), sample completion rate
(≥90%), minor allele frequency (≥0.03) and non-deviation
from the Hardy-Weinberg equilibrium (p < 10−6). SNPs on
the X or Y chromosomes or with cluster plot problems
were excluded. Study participants with gender discrepan-
cies and/or labeling errors were removed, as were samples
with evidence of cryptic family relationship (identified
using the genome command in PLINK [31]) and popula-
tion outliers on the basis of their values of the first three
principal components (identified using EIGENSTRAT
software and unlinked SNPs only [32]). Complete geno-
typing was obtained for 298,702 SNPs in 373 (94%) of the
genotyped cases.
The University of California San Francisco (UCSF) study
The UCSF study population consisted of 213 FL cases
included in a population-based case–control study of
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San Francisco Bay area of incident NHL at ages 20–84
years 2001 to 2006. The cases were identified through
rapid case ascertainment methods by the Cancer Preven-
tion Institute of California with case reporting supple-
mented by Surveillance, Epidemiology and End Results
data [33]. Overall, 69% of eligible cases participated in
the study. Diagnostic material was re-reviewed and clas-
sified according to the WHO lymphoma classification by
the study pathologist [28]. Blood and/or buccal specimens
were collected from 87% of the cases within median
27 days from diagnosis. Genotyping of 329,294 SNPs
was performed using the Illumina HumanCNV370-Duo
BeadChip (Illumina, Inc., San Diego, CA). SNPs were
excluded for low call rates (<90%), low minor allele fre-
quency (<0.03), location on the sex chromosomes or clus-
ter plot problems. Non-European samples according to
MDS plot inspection were removed. Vital status and cause
of death were updated through August 2012 through
record linkage with the Greater Bay Area Cancer registry.
Patients were censored at date of death or date of last
known contact.
Selection of SNPs associated with FL outcome and
established FL risk SNPs
Published studies of germline polymorphisms and FL
outcome were found by searching PubMed and Web of
Science (through June 30, 2013). We selected SNPs sta-
tistically significantly (p < 0.05) associated with overall or
lymphoma-specific survival or with time to progression/
treatment in at least one study and investigated the associ-
ation of these with lymphoma-specific death and progres-
sion in SCALE and the Swedish cohort, respectively.
Fifteen studies and 30 SNPs representing 29 separate loci
were identified (Table 1). Genotype data on 22 of these
markers (21 loci) were available through genotyping
(N = 9) or imputation (N = 13). We used 1000 genomes
multi-ethnic reference panel and Impute 2 for imput-
ation (http://mathgen.stats.ox.ac.uk/impute/impute_v2.
html#download_reference_data). A strict threshold was
set to genotypes with probabilities >0.9, SNPs with in-
formation scores >0.8 and call rates >0.9. Six SNPs
strongly associated with FL risk in recent GWAS
[22-26], of which one (rs6457327 in the HLA class II re-
gion) also has been associated with FL prognosis in two
studies [4,18], were also selected for survival analysis.
Statistical analysis
Genome-wide association studies
In SCALE and UCSF separately, we estimated the asso-
ciation of SNPs with lymphoma-specific death using the
Cox proportional hazards model. Time was measured
from diagnosis to lymphoma-specific death or end of
follow-up. Deaths from other causes than lymphomawere censored. Patients without an event were censored
at the time of last known follow-up. The SNPs were
coded as 0, 1 or 2 based on the number of minor alleles,
and treated as continuous variables in the model.
Adjustment was made for age at diagnosis, sex and
population stratification (using the first three dimensions
calculated by using EIGENSTRAT [32] in SCALE and
multidimensional scaling [31] in UCSF; in both cohorts
unlinked SNPs only were used for these calculations).
Data on FLIPI and first-line rituximab was available in
SCALE and the Swedish cohort, respectively, but not in
UCSF, and hence these covariates were not included in
the model. A full meta-analysis of the GWAS results
was performed using the DerSimonian-Laird random
effects method [34]. PLINK v 1.07 (http://pngu.mgh.
harvard.edu/purcell/plink/) [31] and R [35] were used
for these analyses. In complementary analyses, top vari-
ants in the meta-analysis were also adjusted for FLIPI
risk groups (in SCALE) and first-line rituximab (in the
Swedish cohort). The top locus in the meta-analysis was
further explored in a regional association plot, combining
the p-values of association in the meta-analysis, LD data
from 1000 Genomes European population, gene informa-
tion from the UCSC browser, and estimated recombination
rates (http://csg.sph.umich.edu/locuszoom/) [36]. The po-
tential functionality of the top SNPs and SNPs in strong LD
(r2 ≥ 0.8) with these in the 1000 Genomes European popu-
lation were explored using RegulomeDB, which integrates
multiple types of functional data generated by ENCODE
and other sources (http://RegulomeDB.org/) [37].
Investigation of SNPs with reported prognostic impact in FL
and established FL risk SNPs
We investigated the association of the selected candidate
SNPs and established FL risk SNPs with lymphoma-
specific death in SCALE and lymphoma progression in
SCALE Sweden using the same Cox model as in the
GWAS. The proportional hazard assumption was tested
by plotting Schoenfeld residuals against follow-up time;
no violations were found. In complementary analyses,
associated variants were also adjusted for FLIPI risk groups
and first-line rituximab. Also, potential immortal time bias
was assessed in the Swedish cohort by starting follow-up at
date of venipuncture instead of diagnosis. We further ap-
plied the multi-SNP modeling of risk alleles performed in
three previous studies (rs5361, rs3799488, rs1799864 and
rs1800796 [3]; rs4073, rs2069762, rs3212227 and rs454078
[7]; rs1801131, rs1127717 and rs719235 [15]) on the
SCALE dataset. The SNPs were then coded as 0 or 1, based
on the presence of the risk (protective/deleterious) allele
[3,7,15]. The impact of having one, two or three or more as
compared to no risk alleles on lymphoma-specific death
was assessed in a Cox model, adjusting for age and sex.
Multiple testing was adjusted for with the Bonferroni
Table 1 List of single nucleotide polymorphisms (SNPs) associated with follicular lymphoma outcome (p < 0.05) in at least one previously published study, and
results for these variants in other previous studies






Outcome Relative risk ratio # Studies reporting
no association [refs]
1 C1qA rs172378 A/G Racilia 2008 133 3 PFS 2.5 (2.0, 3.1) none
1 CD46 rs2466571 C/A Charbonneau 2012 107 167 EFS 1.49 (0.86, 2.61), ptrend < 0.05 none
1 CD55 rs2564978 T/C Charbonneau 2012 107 167 EFS 0.52 (0.30, 0.88) none
1 CFH rs1065489 T/G Charbonneau 2012 107 167 EFS 0.44 (0.24, 0.81) none
1 CFH rs1329423 C/T Charbonneau 2012 107 167 EFS 0.49 (0.29, 0.82) none
1 CFH rs3766404 G/A Charbonneau 2012 107 167 EFS 2.25 (1.31, 3.87) none
1 CFHR1 rs436719A C/A Charbonneau 2012 107 167 EFS 0.57 (0.34, 0.96) none
1 CFHR5 rs6694672 G/T Charbonneau 2012 107 167 EFS 2.63 (1.41, 4.92) none
1 FCGR2A rs1801274 A/G Weng 2003 87 2 PFS Decreased rate, plog-rank < 0.02 4 [10,13,14,16]
A/G Cerhan 2007 278 73 OS 0.58 (0.31, 1.04), ptrend = 0.04 2 [10,13]
1 FCGR3A rs396991A G/T Weng 2003 87 2 PFS Decreased rate, plog-rank < 0.03 5 [6,10,13,14,16]
G/T Ghielmini 2005 185 1 EFS 0.5 (0.3, 0.9) 1 [5]
G/T Persky 2012 142 2 OS 0.33 (0.11; 0.96) 1 [10]
G/T Cartron 2002 49 2 RR 1.5 (1.2, 1.9) 1 [10]
1 MTHFR rs1801131 C/A Wang 2009 192 66 OS 2.00 (1.04, 3.84) none
1 SELE rs5361 Aschenbrook- Kilfoy 2012 117 82 OS 0.10 (0.02, 0.48) 1 [7]
2 IL1RN rs454078 T/A Cerhan 2007 278 73 OS 0.50 (0.28, 0.87) 1 [3]
3 CCR2 rs1799864A Aschenbrook- Kilfoy 2012 117 82 OS 0.27 (0.08, 0.86) 1 [7]
3 FTHFD rs1127717 G/A Wang 2009 192 66 OS 1.99 (1.07, 3.7) none
4 IL2 rs2069762 G/T Cerhan 2007 278 73 OS 1.81 (1.06, 3.07) none
4 IL8 rs4073 T/A Aschenbrook- Kilfoy 2012 117 82 OS 2.60 (1.10, 6.15) none
A/T Cerhan 2007 278 73 OS 0.47 (0.27, 0.79), ptrend = 0.06 none
4 IL8 rs2227307 T/G Aschenbrook- Kilfoy 2012 117 82 OS 2.57 (1.07, 6.17) none
G/T Cerhan 2007 278 73 OS 0.53 (0.31, 0.91), ptrend = 0.11 none
4 IRF2 rs3775567A T/ Gibson 2012A 244 6679 OS 3.18 (1.72, 5.87) none
5 C9 rs1421094 A/G Charbonneau 2012 107 167 EFS 0.54 (0.32, 0.90) none
5 IL12B rs3212227 C/A Cerhan 2007 278 73 OS 2.01 (1.18, 3.42) none
6 C6orf15 rs6457327 A/C Wrench 2011 218 2 TTT 2.25. (1.16, 4.36) none
Berglund 2011 102 1 OS Increased rate, p = 0.006 none
6 IFNGR1 rs3799488 Aschenbrook- Kilfoy 2012 117 82 OS 3.19 (1.09, 9.34) 1 [7]



















Table 1 List of single nucleotide polymorphisms (SNPs) associated with follicular lymphoma outcome (p < 0.05) in at least one previously published study, and
results for these variants in other previous studies (Continued)
9 GALNT12 rs10987898A G/ Gibson 2012A 244 6679 OS 0.48 (0.27, 0.83) none
9 GALNT12 rs10819377 T/ Gibson 2012A 244 6679 OS 0.62 (0.36, 1.03), ptrend < 0.001 none
11 CXCR5 rs1790192 G/A Charbonneau 2013A 172 10 EFS 0.64 (0.47; 0.87) none
16 IL4R rs1801275 Aschenbrook- Kilfoy 2012 117 82 OS 2.35 (1.07, 5.19) none
20 BMP7 rs6025446A G/A Gibson 2012A 244 6679 OS 0.41 (0.21, 0.69) none
22 MIF rs755622 Aschenbrook- Kilfoy 2012 117 82 OS 2.45 (1.09,5.47) none
EFS = event-free survival, PFS = progression-free survival, OS = overall survival, TTT = time to transformation, RR = response to Rituximab. R = Rituximab, KM = Kaplan-Meier curve. AVariant was not available for evaluation
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calculations were performed in R (using survSNP) [35].
Results
Patient characteristics
The Danish-Swedish FL cohort was followed for a me-
dian of 8.9 years from diagnosis (range 4.3 months to
12.1 years). Median age at diagnosis was 57 years and
65% had Ann Arbor stage III or IV disease (Table 2).
One-hundred thirty-seven patients (37%) died of which
88 deaths (64%) were classified as lymphoma-specific.Table 2 Characteristics of the study participants with follicula
(SCALE) study (Denmark/Sweden) and in the University of Ca
SCALE overall N (%) Sw
Number of participants 373 23
Sex (men) 185 (50) 11
Age (years)
18-34 9 (2) 6
35-44 30 (8) 15
45-54 105 (27) 58
55-64 139 (36) 83
65-75 100 (26) 69
76-84 - -
Median (range) 57 (22–74) 58
Participant born in Sweden or Denmark (yes) 342 (92) 20
Parents born in Sweden or Denmark (yes) 331 (89) 19
Participants of European ancestryB - -
Ann Arbor stage
I 77 (22) 50
II 48 (13) 32
III 100 (28) 69
IV 133 (37) 68
Missing 15 13
FLIPIA
Low risk 136 (36) 10
Intermediate risk 152 (41) 68
High risk 85 (23) 56
Progression (yes) - 15
Missing - 2
Transformation (yes) - 56
Missing - 12
Rituximab first line/any treatment line (yes) - 24
Missing - 5
Died 137 (37) 88
Died due to lymphoma 88 (24) 54
AThe Swedish patients were classified according to the number of FLIPI risk factors.
age and stage only.
BNon-European samples according to MDS plot inspection were removed in UCSF.The UCSF cohort was followed for a median of 7.5 years
(range 6.9 months to 10.3 years). Twenty-six percent
(N = 56) died, of which 43% (N = 24) were classified
as lymphoma-specific deaths. In Swedish patients, pro-
gression occurred in 67% (N = 155), and rituximab
was used in first-line treatment in 10% and overall in
47%. Overall survival differed as expected between
risk groups defined by FLIPI (low, intermediate, high;
plog-rank < 0.05) in the total SCALE study population and
in the Swedish and Danish populations separately (data
not shown).r lymphoma in the Scandinavian Lymphoma Etiology
lifornia San Francisco (UCSF) study
edish FL cases N (%) Danish FL cases N (%) UCSF FL cases N (%)
1 (62) 142 (38) 213
1 (48) 74 (52) 110 (52)
(3) 2 (1) 3 (1)
(6) 13 (9) 15 (7)
(25) 43 (30) 50 (23)
(36) 53 (37) 73 (34)
(30) 31 (22) 42 (20)
- 30 (14)
(22–74) 56 (33–72) 60 (29–84)
3 (88) 139 (98) -
3 (84) 138 (97) -
- 213 (100)
(23) 27 (19) -
(15) 16 (12) -
(32) 31 (22) -
(31) 65 (47) -
2 -
7 (46) 29 (20) -
(29) 84 (59) -
(24) 29 (20) -




(10)/106 (47) - -
(2) - -
(38) 49 (35) 56 (26)
(23) 34 (24) 24 (11)
The Danish patients were classified according to a modified FLIPI, based on
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In SCALE and UCSF separately, no variants were associ-
ated with lymphoma-specific death at a genome-wide
significant level (p ≤ 5.0 × 10−8). Thirteen variants in
SCALE (on chromosomes 1, 4, 8 and 17; Additional file 1:
Figure S1a) and five variants in UCSF (on chromosomes 1,
2, 6, 9 and 20; Additional file 1: Figure S1b) were associ-
ated with lymphoma-specific death with a p ≤ 10−6, which
was more than would be expected by chance (Additional
file 1: Figure S2a and S2b).
In the meta-analysis of the 298,702 variants in SCALE
and 319,693 in UCSF, 295,134 variants were present in
both cohorts. No variant reached genome-wide signifi-
cant level of association (p < 5.0 × 10−8). The strongest
signals were observed for SNPs on chromosome 1, 4, 17
and 19 (Additional fle 1: Figure S3), for which the p-values
were smaller than would be expected by chance
(Additional file 1: Figure S4). The strongest association with
lymphoma-specific death was observed at rs10491178
(HRrandom = 3.17, 95% CI 2.09-4.79, prandom = 5.24 × 10
−8),
located on 17q24 in the ATP binding cassette A10 gene
(ABCA10) (Table 3). An additional five SNPs on 17q24,
close to ABCA6, showed similar associations and were in
strong linkage disequilibrium (LD) with rs10491178 (r2 ≥
0.96 in the SCALE cohort; Additional file 1: Figure S5).
One SNP on chromosome 1 showed a suggestive associ-
ation of prandom = 10
−7 (rs3131729 HRrandom = 2.45, 95% CI
1.75-3.44, prandom = 2.22 × 10
−7; Table 3). Another SNP on
chromosome 1 showed similar association and was linked
with rs3131729 (r2 = 0.7) (Additional file 1: Table S1).
One intergenic variant on chromosome 4 (rs11932201
HRrandom = 2.16, 95% CI 1.57-2.97, prandom = 2.24 × 10
−6)
and one variant located on 19q13 (rs2250066 HRrandom =
2.11, 95% CI 1.52-2.94, prandom = 9.38 ×10
−6) also showed
suggestive associations at prandom = 10
−6 (Table 3). For
these ten top SNPs, there was no indication of hetero-
geneity between the studies (pheterogeneity > 0.05, I
2 = 0;
Additional file 1: Table S1).
Among the top 48 SNPs in the UCSF GWAS with
p ≤ 10−5 seven were not genotyped in SCALE. We were
able to impute six of these with high confidence (informa-
tion score >0.8). The meta-analysis of these SNPs gave no
additional suggestive associations (data not shown).
There was no correlation between rs10491178 and
performance status, lactate dehydrogenase level (Swedish
cohort, N = 231) or FLIPI risk groups (SCALE cohort,
N = 373; Fisher’s Exact test p ≥ 0.15; data not shown).
For rs10491178, rs3131729, rs11932201 and rs2250066,
additional adjustment for FLIPI and first-line rituximab
in SCALE and the Swedish cohort, respectively, did not
alter the results meaningfully (data not shown). The associ-
ation of the top SNP at 17q24 with overall survival (SCALE)
was weaker compared with lymphoma-specific death
(rs10491178 HR = 2.00, 95% CI 1.35-2.97, p = 5.68 × 10−4),and there was no association with lymphoma progression
(Swedish cohort; Additional file 1: Table S2).
Combining data in the RegulomeDB suggested a puta-
tive functional role for six of the ten top SNPs, of which
rs10491178 (chr 17), rs11932201 (chr 4) and rs2250066
(chr 19) had RegulomeDB scores of 5, indicating that
they may affect transcription factor binding or are lo-
cated in a DNAse hypersensitivity site. There was no
data for rs3131729 (chr 1). The lowest RegulomeDB
score (i.e. strongest evidence of being in a regulatory
site) among our top SNPs and highly linked variants
(r2 ≥ 0.8) was found at the SNP rs113464685 in ABCA10
(score 3b), in LD with rs10491178 (data not shown).
After imputing the genotypes for rs113464685 in SCALE
(as described in Methods for the candidate gene SNPs),
we ran the Cox regression for this SNP and found esti-
mates for lymphoma-specific death virtually identical to
those of the other SNPs on 17q24 (HR = 3.10, 95% CI
1.98-4.89, p = 1.12 × 10−6).
Investigation of SNPs with reported prognostic impact in
FL and established FL risk SNPs
For lymphoma-specific death (SCALE cohort, N = 373),
we had ≥80% power to detect HR ≥ 2.0 (or ≤0.5) for rare
variants (minor allele frequency (MAF) =0.09 [8]) and
HR ≥ 1.5 (or ≤0.67) for more common variants (MAF =
0.49) (Additionl file 1: Figure S6). For lymphoma progres-
sion (Swedish cohort, N = 231), we had ≥80% power to
detect an HR ≥ 1.75 (or ≤0.57) for variants with
MAF ≥0.09. Among the 22 candidate SNPs evaluated,
two imputed variants showed nominally significant
association (p < 0.05) with lymphoma-specific death:
rs1801131 in MTHFR (HR = 0.69, 95% CI 0.49-0.97,
p = 0.03) and rs2069762 in IL2 (HR = 0.63, 95% CI
0.43-0.92, p = 0.02; Table 4). rs1801131 was also associ-
ated with lymphoma progression (HR = 0.59, 95% CI
0.45-0.77, p = 0.0001). The direction of association for
rs1801131 and rs2069762 with the two lymphoma-
specific outcomes was opposite of what was previously
reported for overall survival (Table 1) [7,15]. In line
with a previous study investigating event-free survival
in FL [8], we found that the C allele of rs2466571 in
the CD46 gene was associated with shorter time to
lymphoma progression (HR = 1.37, 95% CI 1.10-1.72,
p = 0.006; Table 4). Likewise, the estimates for two im-
puted tightly linked SNPs (r2 = 0.99) in the IL8 gene,
rs4073 and rs2227307 (HRrs4073 = 0.78, 95% CI 0.62-
0.97, p = 0.02; HRrs2227307 = 0.75, 95% CI 0.60-0.94, p =
0.01), and lymphoma progression were in the same dir-
ection as in two previous studies investigating overall
survival in FL (Table 4) [3,7]. Additional adjustment
with FLIPI categories or first-line rituximab only mar-
ginally altered these results (data not shown). Starting
follow-up at date of venipuncture instead of diagnosis
Table 3 Top single-nucleotide polymorphisms (SNPs) associated with lymphoma-specific deathA (prandom ≤ 10
−6) in the meta-analysis of FL patients in SCALE
and UCSF (N = 586)
SCALE UCSF Meta-analysis Heterogeneity
Chr SNP Position A1 A2 MAF HR (95% CI) pSCALE HR (95% CI) pUCSF HR (95% CI) pRANDOM pHET I
2 Gene Left gene Right gene
17 rs10491178 64661568 A G 0.06 3.10 (1.97; 4.89) 1.13E-06 3.50 (1.28; 9.53) 1.36E-02 3.17 (2.09; 4.79) 5.24E-08 0.83 0 ABCA10 ABCA6 LOC100133319
1 rs3131729 57971355 A G 0.13 2.58 (1.77; 3.76) 9.24E-07 2.00 (0.92; 4.31) 7.58E-02 2.45 (1.75; 3.44) 2.22E-07 0.56 0 DAB1 C8B LOC729423
4 rs11932201 14304530 C A 0.17 2.10 (1.48; 2.97) 2.93E-05 2.50 (1.13; 5.55) 2.29E-02 2.16 (1.57; 2.97) 2.24E-06 0.69 0 NA LOC152742 LOC441009
19 rs2250066 56220931 A G 0.15 2.07 (1.45; 2.97) 7.31E-05 2.35 (1.01; 5.44) 4.40E-02 2.11 (1.52; 2.94) 9.38E-06 0.79 0 KLK11 KLK10 KLK12
A2 =major allele, MAF =minor allele frequency, SCALE = Scandinavian lymphoma etiology study, UCSF = University of California, San Francisco, NA = not applicable.
AEstimated with Hazard ratio, HR, and 95% confidence interval, CI, adjusting for age at diagnosis and three principal components.
BMAF calculated in SCALE.



















Table 4 Relative riskA of lymphoma-specific death and lymphoma progression for selected SNPs previously associated
with any follicular lymphoma outcome in at least one previous study
Lymphoma-specific death ProgressionB
Chr Gene SNP Position A1 A2 MAF HR (95% CI)A p-value HR (95% CI)A p-value
1 CD46 rs2466571 206006669 A C 0.49 0.98 (0.73; 1.32) 0.90 1.37 (1.10; 1.72) 0.006
1 CD55 rs2564978C 205561039 T C 0.31 0.88 (0.62; 1.25) 0.47 1.13 (0.86; 1.49) 0.38
1 CFH rs1065489 194976397 A C 0.15 0.89 (0.57; 1.39) 0.60 0.92 (0.65; 1.31) 0.66
1 CFH rs1329423C 194913010 C T 0.22 0.94 (0.66; 1.39) 0.81 1.06 (0.79; 1.42) 0.71
1 CFH rs3766404 194918455 G A 0.16 1.14 (0.77; 1.68) 0.51 1.12 (0.80; 1.55) 0.52
1 CFHR5 rs6694672C 195212412 G T 0.09 1.01 (0.61; 1.67) 0.97 1.02 (0.66; 1.57) 0.93
1 FCGR2A rs1801274 159746369 A G 0.47 0.76 (0.56; 1.03) 0.08 0.86 (0.68; 1.08) 0.19
1 MTHFR rs1801131C 11777063 G T 0.32 0.69 (0.49; 0.97) 0.03 0.59 (0.45; 0.77) 0.0001E
1 SELE rs5361 167967684 C A 0.11 1.04 (0.64; 1.69) 0.89 0.90 (0.61; 1.32) 0.59
2 IL1RN rs454078C 113605264 T A 0.28 0.99 (0.69; 1.42) 0.96 0.94 (0.72; 1.23) 0.66
3 FTHFD rs1127717C 127308749 C T 0.16 0.91 (0.58; 1.43) 0.69 0.98 (0.70; 1.38) 0.92
4 IL2 rs2069762C 123597430 C A 0.26 0.63 (0.43; 0.92) 0.02 0.89 (0.69; 1.16) 0.38
4 IL8 rs4073C 74824888 A T 0.46 0.93 (0.70; 1.25) 0.64 0.78 (0.62; 0.97) 0.02
4 IL8 rs2227307C 74825533 G T 0.45 0.93 (0.69; 1.25) 0.63 0.75 (0.60; 0.94) 0.01
5 C9 rs1421094C 39391348 A G 0.37 1.19 (0.88; 1.61) 0.27 1.00 (0.79; 1.27) 0.98
5 IL12B rs3212227C 158675528 G T 0.17 1.21 (0.81; 1.80) 0.36 1.42 (1.03; 1.94) 0.03
6 C6orf15 rs6457327D 31182009 A C 0.42 0.90 (0.66; 1.24) 0.53 0.90 (0.71; 1.14) 0.38
6 IFNGR1 rs3799488 137561473 G A 0.12 0.76 (0.46; 1.24) 0.27 1.12 (0.79; 1.57) 0.53
8 GGH rs719235C 64114235 A C 0.32 0.96 (0.69; 1.34) 0.82 1.00 (0.77; 1.29) 0.99
9 GALNT12 rs10819377 100643533 A G 0.46 0.76 (0.56; 1.03) 0.07 0.89 (0.71; 1.12) 0.33
16 IL4R rs1801275 27281901 G A 0.25 0.91 (0.64; 1.30) 0.62 0.85 (0.65; 1.12) 0.26
22 MIF rs755622C 22566392 C G 0.16 0.76 (0.49; 1.16) 0.20 0.85 (0.61; 1.18) 0.34
AEstimated with Hazard ratio, HR, and 95% confidence interval, CI. Adjusted for age at diagnosis, sex and three principal components.
BSwedish cases only (n = 231) for time to progression.
CImputed SNP.
Drs6457327 has previously been associated with both FL risk and prognosis.
EOpposite direction of association to previous study [15].
The minor allele (A1) was investigated for association except for rs2466571 (CD46), where the major allele (A2) was used as reference for easier comparison with
previous study result.
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correcting for performing 54 tests (27 SNPs and two out-
comes), the association of rs1801131 (MTHFR) with
lymphoma progression remained significant (Bonferroni
corrected p = 0.01).
We finally stratified patients by the number of deleteri-
ous/protective alleles, as defined in three previous studies
[3,7,15], but found no significant associations with the out-
comes in the present study (data not shown). None of the
six SNPs previously reported to be associated with risk of
FL [22-26] were significantly associated with lymphoma-
specific death or progression (Table 4 (rs6457327) and
Additional file 1: Table S3).
Discussion
In this GWAS meta-analysis of common genetic vari-
ation in FL prognosis in a total of 586 patients, we did
not identify any variants associated with lymphoma-specific death at a genome-wide significant level
(p < 5.0 ×10−8). The strongest association was observed for
tightly linked SNPs located on 17q24 near the ABCA10
and ABCA6 genes (rs10491178 HRrandom = 3.17, 95% CI
2.09-4.79, prandom = 5.24 ×10
−8). Investigating previously
reported candidate genes, we found further support of a
role for rs2466571 in CD46 in FL progression. Two SNPs
in IL8 (rs4073 and rs2227307) previously linked with over-
all survival in FL, where here associated with FL progres-
sion. We also observed an association with MTHFR and
FL progression but the direction was opposite of a previ-
ous report on overall survival in FL.
Genome-wide association study and meta-analysis
The increased rate of lymphoma-specific death for car-
riers of the A allele of rs10491178 in ABCA10 on 17p24
was consistent in the SCALE and UCSF cohorts,
strengthening the notion of a possible causal association
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established prognostic risk factors (lactate dehydrogen-
ase levels, performance status and FLIPI). ABCA10 is
clustered among four other members of the ATP bind-
ing cassette (ABC) 1 family on 17q24, including ABCA6
harboring another five linked associated SNP markers.
The ABC transporters - a family of proteins responsible
for the movement of a wide variety of xenobiotics, lipids
and metabolic products across the cell membranes - are
implicated in multidrug resistance [39]. They are overex-
pressed in several tumor types [39], including FL [40].
The exact function of ABCA10 and ABCA6 remains to
be elucidated [41], but the ABCA3 transporter, similar
in terms of amino acid sequences and structural
organization to ABCA10 and ABCA6 [41], has been
shown to impede the efficacy of rituximab in aggressive
B-cell lymphomas, and vincristine, anthracyclines and
etopside in acute myeloid leukemia when expressed in
high levels [42]. Interestingly, rs10491178 (C > T) en-
codes a premature stop codon (Arg (CGA) – > Stop
(TGA)) in the ABCA10 transcript (Refseq NM_080282;
Ensembl ABCA10-001) [43].
We also looked up SNPs in high LD (r2 > 0.8) with
rs10491178 for potential regulatory functions in Regulo-
meDB, and identified another SNP rs113464685 in
ABCA10, in strong LD (r2 = 1.00) with the top SNPs at
17q24, that lies in the binding site of the transcription
factor paired box 5 (PAX5). PAX5 has a pivotal regula-
tory function in B-cell development and its aberrant
expression is correlated with aggressive subsets of B-cell
NHL [44]. This SNP is thus an alternative candidate to
explain the observed association with the region.
The suggestive associations (p ≤ 10−6) of rs3131729 in
the Dab, reelin signal transducer, homolog 1 (DAB1)
gene on 1p32-p31, the intergenic SNP rs11932201 on
chromosome 4, and rs2250066 in the kallikrein (KLK) 11
gene on 19q13, were also consistent in the SCALE and
UCSF studies. The role of the DAB1 protein in the devel-
oping nervous system is well studied but for other tissues
knowledge is scarce [45]. rs11932201 is flanked by two
genes (long intergenic non-protein coding RNA 1085
(LINC01085) and CPEB2 antisense RNA 1 (CPEB2-AS1))
of which little is known. The KLK locus on 19q13 harbors
genes encoding a family of serine proteases associated
with cancer risk and prognosis in several studies [46].
Investigation of SNPs with reported prognostic impact in
FL and established FL risk SNPs
Upon investigating SNPs linked to FL survival in previ-
ous studies, we observed a shorter time to lymphoma
progression for C compared to A allele carriers at
rs2466571 in CD46 on 1q32 (HR = 1.37, ptrend = 0.006),
at a nominally significant level. This is consistent with a
recent study of 107 FL patients investigating event-freesurvival in FL (HR = 1.49, ptrend < 0.05) [8]. CD46 is a
complement inhibitor, protecting the cell against
complement-mediated lysis [47]. High expression levels
of membrane-bound complement regulatory proteins
such as CD46 in tumors has been shown to suppress
anti-tumor T-cell responses, and may inhibit anti-tumor
therapeutic activity of monoclonal antibodies, including
rituximab in B-cell NHL [47].
The minor alleles of two SNPs in IL8, rs4073 and
rs2227307, on 4q12-q21 were associated with longer time
to progression (rs4073 HRA = 0.78, p = 0.02; rs2227307
HRG = 0.75, p = 0.01). Two previous studies reported an
association for the same two SNPs with overall survival
in FL; Cerhan et al. observed a statistically significant
longer overall survival with homozygosity of the
same alleles (rs4073 HRAA = 0.47, 95% CI 0.27-0.79,
rs2227307 HRGG = 0.53, 95% CI 0.31-0.91) [7], whereas
Aschebrook-Kilfoy et al. observed that the opposite
alleles were associated with shorter overall survival
(rs4073 HRTT = 2.60, 95% CI 1.10-6.15, rs2227307
HRCC = 2.57, 95% CI 1.07-6.17) [3] (Table 1). Time to
FL progression was not evaluated in these former in-
vestigations. The A allele of rs4073 has been associated
with increased production of IL8 [48].
In our study, rs1801131 in MTHFR was associated
with time to progression and lymphoma-specific death,
and rs2069762 in the promoter of IL2 with lymphoma-
specific death. However, these results are conflicting
with previous reports of overall survival in FL and are
therefore difficult to interpret [7,15]. For rs1801274, lo-
cated in FCGR2A on 1q23, one of the two most studied
variants [5-7,10,13,14,16,17], we observed no associa-
tions with lymphoma progression or lymphoma-specific
death. This is in line with the results of most previous
studies, irrespective of how outcome was defined (pro-
gression-free [6,10,14,16,17], event-free [5,6] or overall
survival [5,7]).
Several SNPs, including rs6457327, rs10484561 and
rs2647012 in the HLA class I and II regions on 6p21,
are convincingly associated with FL risk [22,24,25], sug-
gesting an important role of this genetic region in the
development of FL, and thereby possibly also in FL
progression. Indeed, rs6457327 has been associated with
FL transformation [4,18] and overall survival [4] in two
previous studies (Table 1). However, we did not observe
any clear associations for rs6457327, rs10484561 and
rs2647012 with FL progression or lymphoma-specific
death in our cohort.
Strengths and weaknesses
The strengths of the present analysis include the
population-based design of the two cohorts, the large
number of patients compared to previous studies, and
the comprehensive evaluation of the impact of genetic
Baecklund et al. BMC Medical Genetics 2014, 15:113 Page 11 of 13
http://www.biomedcentral.com/1471-2350/15/113variation in FL outcome. Population stratification was
adjusted for in the GWAS and we observed little or no
evidence of inflation of the statistics (lambda GCSCALE =
lambda GCUCSF = 1.00) [49]. In the analysis of candidate
gene variants and lymphoma progression or death, adjust-
ment for established risk factors including age, sex, FLIPI
categories and first-line rituximab resulted in marginal
changes of the point estimates only.
Although candidate gene studies have obvious weak-
nesses compared with genome-wide studies, a strength
include a higher prior probability of true findings, since
they are based on a biological understanding of cancer
survival pathways [50]. Still, many candidate gene find-
ings cannot be replicated, suggesting some false-positive
results in the existing literature [50]. Most of the previ-
ous studies were small (N < 150) and the number of
SNPs tested were sometimes large (up to 6679 variants),
resulting in a considerable risk of chance findings. How-
ever, the present study was limited to detect moderate to
strong effects (HR >1.5-2.0) for the investigated SNPs
with acceptable probability (≥0.80). Hence, chance find-
ings cannot be excluded.
In the study of genetic variation and FL prognosis, dif-
ferent outcome measures have been used, including
overall and lymphoma-specific survival and event-free
survival. Progression-free survival, defined as the time
from study entry to lymphoma progression or all-cause
death, is generally recognized as the most valid measure
in intervention studies [51]. We argue that lymphoma-
specific survival/death may be superior to overall sur-
vival (but not to progression-free survival) if the study
aims to test an association with lymphoma progression
leading to death. In view of the high median age at diag-
nosis of FL and the often indolent clinical course [1], a
relatively large proportion of the patients are expected
to die of non-lymphoma related causes, which could di-
lute associations with lymphoma progression and death
if overall survival is used instead. On the other hand,
with the use of lymphoma-specific survival some deaths
due in part to progression may have been missed poten-
tially leading to a lower specificity. We did not observe
similar results for three out of four top genetic variants
and lymphoma progression, as with lymphoma-specific
death, although this analysis could only be performed in
a subset of the patients. Explanations for such a differ-
ence could lie in the definitions of these outcomes.
While time to progression and progression-free survival
primarily reflect the first part of the follow-up period,
including mainly time to first-line or second-line treat-
ment, time to lymphoma-specific death reflects a
larger part of the follow-up and thus, to a higher de-
gree, treatment response or lack of such. In the future,
attempts to validate the current findings, and when
comparing results between investigations, the use ofsimilar definitions of outcome will be important for
the interpretation.
Conclusions
In the present GWAS meta-analysis, there was suggestive
evidence that inherited polymorphisms in the ABCA10 or
ABCA6 genes may be associated with risk of lymphoma-
specific death. In candidate-gene analysis, an association
with lymphoma progression was observed for SNPs in
CD46 and IL8, previously linked with lymphoma progres-
sion (CD46) and overall survival (IL8). These findings
need further confirmation in other independent popula-
tions or in a larger multicenter GWAS.
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Additional file 1: Table S1. Top SNPs associated with lymphoma-specific
death (prandom<5.0 x10-5) in the meta-analysis of FL patients in SCALE
and UCSF (N=586). The minor allele (A1) was investigated for association.
A2=major allele, MAF= minor allele frequency, NA= not applicable.
Table S2. Relative risk of lymphoma-specific and all-cause death in
SCALE (N=373), and lymphoma progression in SCALE Sweden (N=231)
for the top SNPs in the pooled analysis of SCALE and UCSF. The minor
allele was investigated for association. Table S3. Relative risk of
lymphoma-specific death and lymphoma progression for SNPs previously
associated with follicular lymphoma risk. Figure S1. Manhattan plot of the
-log10(p-values) for the association with lymphoma-specific death in SCALE
(A) and UCSF (B), by chromosome and within chromosome location. The
top ten SNPs in the meta-analysis are highlighted (light green). The red
line marks -log10(5.0 x10-8). Figure S2. QQ plot of the observed versus the
expected -log(p-values) for the association with lymphoma-specific death in
SCALE (A) and UCSF (B). Figure S3. Manhattan plot of the -log10(p-values)
for the association with lymphoma-specific death in the meta-analysis of
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line marks -log10(5.0 x10-8). Figure S4. QQ plot of the observed versus the
expected -log(p-values) for the association with lymphoma-specific death in
the meta-analysis of SCALE and UCSF. Figure S5. Regional association plot
of the top locus in the combined analysis on 17q, displaying the p-values
of association in SCALE, extent of LD with rs10491178 as reference, relation
of SNPs and genes, and estimated recombination rates at each position.
Figure S6. Estimations of the power to detect associations between selected
candidate SNPs and lymphoma-specific death and lymphoma progression,
respectively, for different effect sizes and minor allele frequencies (MAF).
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